VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations

Cancer Research

Volumn 71, Issue 16, 2011, Pages 5500-5511

  Rechsteiner, Markus P ^a   Von Teichman, Adriana ^a   Nowicka, Anna ^a   Sulser, Tullio ^a   Schraml, Peter ^a   Moch, Holger ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ELONGIN B; ELONGIN C; GREEN FLUORESCENT PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLASMID VECTOR; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; EXON; GENE; GENE ACTIVITY; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STABILITY; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; VHL GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MIDDLE AGED; MUTATION, MISSENSE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 80051697173     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0757     Document Type: Article

References (51)

1. Cancer Mondial. International Agency for Research on Cancer, World Health Organization, Lyon, France. Available from: http://www-dep.iarc.fr.
2. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006;66:2000-11.
3. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-7.
4. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5. (Pubitemid 29246458)
5. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003;23:9361-74. (Pubitemid 37499822)
6. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005;25:5675-86. (Pubitemid 40853601)
7. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007;17:71-7. (Pubitemid 46109295)
8. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O. Inhibition of hypoxiainducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2004;2:89-95. (Pubitemid 38250425)
9. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83.
10. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-46.
11. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007;11:335-47. (Pubitemid 46518312)
12. Yoo YG, Christensen J, Huang LE. HIF-1{alpha} confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function. Cancer Res 2011;71:1244-52.
13. The Universal Mutation Database: The VHL Mutations Database. Montpellier, France. Available from: http://www.umd.be/VHL/.
14. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 2009;15:7582-92.
15. Schraml P, Struckmann K, Hatz F, Sonnet S, Kully C, Gasser T, et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002;196:186-93. (Pubitemid 34110900)
16. Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 2010;7:277-88.
17. Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 2007;28:143-9. (Pubitemid 46233311)
18. Forman JR, Worth CL, Bickerton GR, Eisen TG, Blundell TL. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis. Proteins 2009;77:84-96.
19. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008;180:860-5; Discussion 5-6.
20. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 2003;5:64-70. (Pubitemid 36054331)
21. Bangiyeva V, Rosenbloom A, Alexander AE, Isanova B, Popko T, Schoenfeld AR. Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes. BMC Cancer 2009;9:229.
22. Hacker KE, Lee CM, Rathmell WK. VHL type 2B mutations retain VBC complex form and function. PLoS One 2008;3:e3801.
23. International classification of diseases (ICD). World Health Organization, Geneva, Switzerland. Available from: http://www.who.int/ classifications/icd/en/.
24. Schraml P, Struckmann K, Hatz F, Sonnet S, Kully C, Gasser T, et al. VHL mutations and their correlation with tumor cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002;196:186-93. (Pubitemid 34110900)
25. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006;66:2000-11.
26. Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 2002;417:975-8. (Pubitemid 34716877)
27. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr., Pavletich NP. Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science 2002;296:1886-9. (Pubitemid 34596278)
28. Worth CL, Bickerton GR, Schreyer A, Forman JR, Cheng TM, Lee S, et al. A structural bioinformatics approach to the analysis of nonsynonymous single nucleotide polymorphisms (nsSNPs) and their relation to disease. J Bioinform Comput Biol 2007;5:1297-318.
29. Ferrer-Costa C, Orozco M, de la Cruz X. Sequence-based prediction of pathological mutations. Proteins 2004;57:811-9. (Pubitemid 39627003)
30. Site Directed Mutator: I-Mutant2.0. Thermodynamic database for protein and mutants. Crystallography and Bioinformatic Group, University of Cambridge, Cambridge, United Kingdom. Available from: http://www-cryst.bioc.cam.ac.uk/~sdm/ sdm.php.
31. Site Directed Mutator: Mupro. Thermodynamic database for protein and mutants. Crystallography and Bioinformatic Group, University of Cambridge, Cambridge, United Kingdom. Available from: http://www-cryst.bioc.cam.ac.uk/~sdm/ sdm.php.
32. Topham CM, Srinivasan N, Blundell TL. Prediction of the stability of protein mutants based on structural environment-dependent amino acid substitution and propensity tables. Protein Eng 1997;10:7-21. (Pubitemid 27073347)
33. Smith RE, Lovell SC, Burke DF, Montalvao RW, Blundell TL. Andante: reducing side-chain rotamer search space during comparative modeling using environment-specific substitution probabilities. Bioinformatics 2007;23:1099-105. (Pubitemid 47050561)
34. Chelliah V, Chen L, Blundell TL, Lovell SC. Distinguishing structural and functional restraints in evolution in order to identify interaction sites. J Mol Biol 2004;342:1487-504. (Pubitemid 39213963)
35. Frew IJ, Krek W. pVHL: a multipurpose adaptor protein. Sci Signal 2008;1:pe30.
36. Schoenfeld A, Davidowitz EJ, Burk RD. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci U S A 1998;95:8817-22. (Pubitemid 28350572)
37. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008;14:4726-34.
38. Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW, et al. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res 2009;69:6660-7.
39. Schoenfeld AR, Davidowitz EJ, Burk RD. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc Natl Acad Sci U S A 2000;97:8507-12. (Pubitemid 30639703)
40. Kamura T, Brower CS, Conaway RC, Conaway JW. A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase. J Biol Chem 2002;277:30388-93.
41. Jung CR, Hwang KS, Yoo J, Cho WK, Kim JM, Kim WH, et al. E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med 2006;12:809-16. (Pubitemid 44050071)
42. Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res 2004;64:8595-603. (Pubitemid 39552072)
43. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 2001;10:1029-38. (Pubitemid 32447780)
44. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001;15:2675-86. (Pubitemid 32988878)
45. Zimmer M, Ebert BL, Neil C, Brenner K, Papaioannou I, Melas A, et al. Small-molecule inhibitors of HIF-2a translation link its 5′UTR iron-responsive element to oxygen sensing. Mol Cell 2008;32:838-48.
46. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007;12:108-13. (Pubitemid 47199124)
47. Wenger RH, Camenisch G, Stiehl DP, Katschinski DM. HIF prolyl-4-hydroxylase interacting proteins: consequences for drug targeting. Curr Pharm Des 2009;15:3886-94.
48. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004;279:38458-65. (Pubitemid 39295997)
49. Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, KaelinWG Jr. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol 2009;29:5729-41.
50. Metzen E, Stiehl DP, Doege K, Marxsen JH, Hellwig-Burgel T, Jelkmann W. Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochem J 2005;387:711-7. (Pubitemid 40685705)
51. Stiehl DP, Wirthner R, Koditz J, Spielmann P, Camenisch G, Wenger RH. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. J Biol Chem 2006;281:23482-91. (Pubitemid 44274123)